ARA-290
ARA-290
ARA-290
ARA-290
Research Peptide Vials

ARA-290

ARA-290 is a non-erythropoietic peptide derived from the helix B surface of EPO. It targets the innate repair receptor (IRR) without activating classical EPO receptors. Research focuses on its cytoprotective, anti-inflammatory, and neuroprotective effects.


Product Name:
Cibinetide
Synonyms:
ARA-290 (Cibinetide);ARA290, >98%;ARA290,Cibinetide, >98%;ARA290;WZTIQQBMSJTRBR-MUZUOSMHSA-N;ara290/Poziotinib;L-Serine, 5-oxo-L-prolyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-α-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-;ARA-290(Cibinetide) acetate
CAS:
1208243-50-8
MF:
C51H84N16O21
MW:
1257.31
EINECS:
200-001-8
Product Categories:
Research Peptide
Cibinetide, also known as ARA 290 and helix B surface peptide (HBSP), is a synthetic 11 amino acid peptide derived from the structure of the B helix of erythropoietin(EPO), with marked anti-apoptotic, anti-inflammatory and anti-permeability effects, recapitulating the effects of the endogenous EPO. Unlike EPO, is not haematopoietic and, thus, is free of the possible side effects of EPO, which can be life threatening. In an experimental model of DR, cibinetide administered systemically inhibited vascular leakage and edema and protected against retinal blood vessels and neuroglial degeneration. Additionally, cibinetide improved metabolic control in both preclinical and clinical studies.